Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment

This study has been withdrawn prior to enrollment.
(No enrollment.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00006091
First received: August 3, 2000
Last updated: October 5, 2012
Last verified: October 2012

August 3, 2000
October 5, 2012
June 2000
January 2002   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00006091 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
Arsenic Trioxide Therapy for Interferon Alpha Refractory or Intolerant Chronic Phase Chronic Myelogenous Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have chronic phase chronic myelogenous leukemia that has not responded to previous treatment.

OBJECTIVES:

I. Determine the rate of complete or major cytogenetic response to arsenic trioxide as demonstrated by a decrease in the percentage of Philadelphia chromosome positive (or breakpoint cluster region bcr positive) cells in the bone marrow in patients with interferon alfa refractory or intolerant chronic phase chronic myelogenous leukemia.

II. Determine the rate and duration of complete hematological response to this treatment in these patients.

III. Determine the duration of complete and major cytogenetic response to this treatment in these patients.

IV. Determine the pattern of clinical adverse experience and improvement in symptomatic parameters with this treatment in these patients.

V. Determine the time to accelerated disease or blast crisis and overall survival in these patients after receiving this treatment.

VI. Determine the effects of this treatment on cytokines, apoptosis, and angiogenesis in these patients.

OUTLINE: Patients receive arsenic trioxide intravenous (IV) over 2 hours either daily for 15 consecutive days or 5 days on, 2 days off for a total of 15 doses. Treatment repeats every 2-5 weeks after the previous course for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission are followed every month for 3 months, every 2 months for 6 months, every 3-4 months for 1 year, and then every 6 months thereafter. All other patients are followed every 3 months for 1 year and then annually thereafter.

PROJECTED ACCRUAL: A total of 17-53 patients will be accrued for this study within 2.5 years.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia
Drug: arsenic trioxide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
January 2002
January 2002   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of Philadelphia (Ph) chromosome positive (or breakpoint cluster region bcr positive) chronic myelogenous leukemia in chronic phase
  • Ineligible for or refused allogeneic bone marrow transplantation
  • Interferon alfa refractory or intolerant as defined by the following:
  • Refractory: Failure to achieve a complete hematologic response lasting for at least 1 month after prior therapy with interferon alfa based regimen for at least 3 months 65% or more Ph positive chromosomes in bone marrow after one year of interferon alfa based therapy
  • At least a 30% increase in Ph positive chromosomes in bone marrow in samples taken at least one month apart OR
  • An increase of at least 65% in Ph positive chromosomes in bone marrow
  • Intolerant: Grade 3 or greater nonhematologic toxicity Autoimmune phenomenon at any grade
  • No accelerated phase or blastic phase disease as defined by the following:
  • Greater than 15% blasts or basophils in the peripheral blood or bone marrow
  • Greater than 30% blasts plus promyelocytes in the peripheral blood or bone marrow
  • Documented extramedullary blastic disease outside liver or spleen
  • Platelet count less than 100,000/mm3 unrelated to therapy
  • Clonal evolution (additional chromosomal abnormalities other than Ph chromosome) as solitary feature is not considered accelerated disease
  • No known brain metastases or central nervous system (CNS) disease

PATIENT CHARACTERISTICS:

  • Age: 12 and over
  • Performance status: Zubrod 0-2
  • Life expectancy: At least 2 years
  • Hematopoietic: See Disease Characteristics
  • Hepatic: Unless due to direct disease infiltration of the liver:
  • ALT and AST no greater than 2.5 times upper limit of normal (ULN)
  • Bilirubin no greater than 1.5 times ULN (unless due to Gilbert's disease)
  • No hepatic disease that would preclude study
  • Renal: Creatinine no greater than 1.5 times ULN Creatinine clearance at least 60 mL/min
  • Cardiovascular: No history of New York Heart Association grade III or IV cardiac disease
  • No cardiovascular disease that would preclude study
  • No unstable angina pectoris or cardiac arrhythmia that would shorten life expectancy
  • Other: No history of grand mal seizures other than infantile febrile seizures
  • No active secondary malignancy or other uncontrolled concurrent medical problem that would shorten life expectancy
  • No neurologic, endocrine, or other major systemic disease that would preclude study
  • No active infection uncontrolled by oral or IV antibiotics
  • No history of hypersensitivity to the study drug or drugs with similar chemical structure
  • No mental condition that would preclude study Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

  • Biologic therapy: See Disease Characteristics
  • No concurrent bone marrow or peripheral blood stem cell transplantation
  • Chemotherapy: At least 14 days since prior chemotherapy (48 hours for hydroxyurea and 6 weeks for busulfan) and recovered (unless evidence of rapidly progressive disease)
  • No other concurrent cytotoxic chemotherapy
  • No prior arsenic trioxide
  • Endocrine therapy: No concurrent steroids for the treatment of neoplasms (except for new adrenal failures)
  • No concurrent hormones for the treatment of neoplasms (except for nondisease related conditions)
  • Radiotherapy: At least 14 days since prior radiotherapy
  • No concurrent radiotherapy
  • Surgery: Not specified
  • Other: At least 14 days since other prior investigational agent
  • No other concurrent investigational or antileukemic agents
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00006091
CDR0000068094, MDA-DM-00058, NCI-311, ID00-058
No
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Study Chair: Deborah A. Thomas, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP